Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Expenditures among young adults with acute lymphoblastic leukemia by site of care.  Cancer.  127:1901-1911. 2021
2021 Poverty and Survival in Childhood Cancer: A Framework to Move Toward Systemic Change 2021
2021 Risk, Racial Disparity, and Outcomes among Patients with Cancer and COVID-19 Infection.  JAMA Oncology.  2021
2020 Preventive health service use among survivors of adolescent and young adult cancer.  Preventive Medicine Reports.  20. 2020
2020 Isolation of DNA-free RNA from human bone marrow mononuclear cells: Comparison of laboratory methods 2020
2020 Adherence to cardiomyopathy screening guidelines among adolescent and young adult cancer survivors exposed to chest radiation and/or anthracyclines.  Journal of Cancer Survivorship.  2020
2019 Lung cancer in nonelderly patients: Facility and patient characteristics associated with not receiving treatment 2019
2018 Causes of inferior outcome in adolescents and young adults with acute lymphoblastic leukemia: Across oncology services and regardless of clinical trial enrollment.  Cancer Epidemiology, Biomarkers and Prevention.  27:1133-1141. 2018
2017 T-cell prolymphocytic leukemia in an adolescent with ataxiatelangiectasia: Novel approach with a JAK3 inhibitor (tofacitinib).  Blood Advances.  1:2724-2728. 2017
2017 Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma.  Leukemia.  31:1450-1453. 2017
2017 Publication outcomes of abstracts from the American Society of Hematology Annual Meeting.  American Journal of Hematology.  92:E81-E83. 2017
2017 Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia: Impact of care at specialized cancer centers on survival outcome.  Cancer Epidemiology, Biomarkers and Prevention.  26:312-320. 2017
2016 Value, access, and cost of cancer care delivery at academic cancer centers 2016
2015 Impact of tailored education on awareness of personal risk for therapy-related complications among childhood cancer survivors.  Journal of Clinical Oncology.  33:3887-3893. 2015
2015 Impact of care at comprehensive cancer centers on outcome: Results from a population-based study.  Cancer.  121:3885-3893. 2015
2015 Long-term pulmonary function in survivors of childhood cancer.  Journal of Clinical Oncology.  33:1592-1600. 2015
2015 Piecing together the puzzle of disparities in adolescents and young adults.  Cancer.  121:1168-1171. 2015
2014 Impact of care at NCI Comprehensive Cancer Centers (NCICCC) on cancer outcome: Results from a population-based study..  Journal of Clinical Oncology.  32:188. 2014
2014 Impact of treatment site in adolescents and young adults with central nervous system tumors 2014
2013 Pitfalls of using administrative data sets to describe clinical outcomes in sickle cell disease 2013
2013 Relapse after treatment of pediatric hodgkin lymphoma: Outcome and role of surveillance after end of therapy 2013
2013 Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens..  British Journal of Haematology.  162:376-382. 2013
2012 Sickle cell disease in California: Sociodemographic predictors of emergency department utilization 2012
2011 Sickle-cell disease in California: A population-based description of emergency department utilization 2011
2010 Health care reform 2010: Expected favorable impact on childhood cancer patients and survivors 2010

Chapter

Year Title Altmetric
2017 Making Ends Meet: Financial Issues from the Perspectives of Patients and Their Health-Care Team.  667-685. 2017

Principal Investigator On

Investigator On

  • AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2020 - 2026
  • AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2021 - 2026
  • ALTE1631, A Randomized Web-Based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2025
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2025
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2025
  • Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2025
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2025
  • AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2025
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2020 - 2025
  • AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2021 - 2025
  • AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2019 - 2024
  • AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2024
  • ADVANCING ALSTATE (Alabama Lifespan Sickle cell Tracking Access Towards Equality) Network  awarded by CDC - Centers for Disease Control and Prevention/DHHS 2020 - 2023
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2023
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2020 - 2023
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2019 - 2022
  • Reduced Burden Of Oncology Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents, and Young Adults with CD20+ Mature B-Cell Lymphoma  awarded by NEW YORK MEDICAL COLLEGE 2017 - 2022
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2018 - 2021
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2021
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2015 - 2021
  • Hyundai Hope on Wheels Impact Grant  awarded by HYUNDAI HOPE ON WHEELS 2018 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2020
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Developing a Network to Utilize Administrative and Clinical Data for Childhood, Adolescent and Young Adult Oncology Survivorship Research  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP 2015 - 2018
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2018
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2018
  • A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2018
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2018
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2017
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2017
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee 2015 - 2016
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2015
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015

    • Education And Training

  • Doctor of Medicine, University of Florida 2002
  • MassGeneral Hospital for Children, Internship 2003
  • Masachusetts General Hospital, Residency 2005
  • Children's Hospital Los Angeles, Postdoctoral Fellowship 2009

    • Full Name

  • Julie Wolfson-Stockman